Research Article| Volume 24, SUPPLEMENT 3, C43-C57, 2002

Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer

  • Leroy Monroe Parker
    Address correspondence to: Leroy Monroe Parker, MD, Department of Medicine, Harvard Medical School, The Dana-Farber Cancer Institute, 44 Binney Street #D1210, Boston, MA 02115-6013
    Department of Medicine, Harvard Medical School, The Dana-Farber Cancer Institute, Boston, Massachusetts USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      Background: Hormonal therapy (HT) is an important consideration in the management of postmenopausal women with metastatic breast cancer. Despite the fact that the advanced-stage disease is virtually incurable, HTs can offer patients disease control equivalent to that of chemotherapy, but with improved quality of life (QOL). Knowledge of the estrogen and progesterone receptor status, as well as other clinical factors, allows for selection of patients who are most likely to benefit from HT. Disease that becomes refractory to an initial HT may respond to another agent or class of HTs. Thus, HTs are generally administered sequentially, delaying the need for cytotoxic chemotherapy, which often reduces QOL. Optimal sequencing is thus one of the more important facets of HT. Prior to the release of a number of newer agents, tamoxifen had been considered as initial HT. At present, more agents exist, including the aromatase inhibitors, progestins, and the estrogen receptor antagonist fulvestrant.
      Objective: This article reviews key trials evaluating the use of sequential HTs.
      Methods: Articles were identified for inclusion in this manuscript through the following searches, limited to English-language publications: MEDLINE (mid 1960s to January 2002), American Society of Oncology abstracts (1997–2001), and San Antonio Breast Cancer Symposium abstracts (2001 and 2002). The following search terms were used: breast cancer, hormonal therapies, tamoxifen, toremifene, letrozole, anastrozole, exemestane, megestrol acetate, fulvestrant, and ICI 182,780.
      Results: Results of Phase III studies have shown many of these agents to be equivalent or superior to tamoxifen and can be used initially to treat patients who either have failed tamoxifen therapy or may be unable to tolerate some of the toxicities associated with tamoxifen. For example, the aromatase inhibitors have been shown to be highly active and tolerable in postmenopausal women with breast cancer who have failed tamoxifen therapy or who are naive to HT. Other clinical trials have demonstrated the efficacy of fulvestrant in patients with metastatic breast cancer who are tamoxifen-resistant, and have shown fulvestrant to be at least as effective as anastrozole in tamoxifen-resistant patients.
      Conclusions: Although the optimum sequence of HTs remains controversial, using the newer agents as initial or subsequent therapy should improve QOL and may improve overall survival.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cole MP
        • Jones CT
        • Todd ID
        A new anti-oestrogenic agent in late breast cancer: An early clinical appraisal of ICI46474.
        Br J Cancer. 1971; 25: 270-275
        • Cash R
        • Brough AJ
        • Cohen MN
        • Satoh PS
        Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: Mechanism of action and therapeutic trial.
        J Clin Endocrinol Metab. 1967; 27: 1239-1248
        • Jensen EV
        • Jacobson HI
        Basic guides to the mechanism of estrogen action.
        Recent Prog Horm Res. 1962; 18: 387-414
        • Sedlacek SM
        • Horwitz KB
        The role of progestins and progesterone receptors in the treatment of breast cancer.
        Steroids. 1984; 44: 467-484
        • Buzdar AU
        Endocrine therapy in the treatment of metastatic breast cancer.
        Semin Oncol. 2001; 28: 291-304
      1. Tamoxifen for early breast cancer: An overview of the randomised trials.
        Lancet. 1998; 351 (Early Breast Cancer Trialists' Collaborative Group): 1451-1467
        • Fisher B
        • Costantino JP
        • Wickerham DL
        • et al.
        Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
        J Natl Cancer Inst. 1998; 90: 1371-1388
        • Cummings SR
        • Eckert S
        • Krueger KA
        • et al.
        The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Eval.
        JAMA. 1999; 281: 2189-2197
        • Goldhirsch A
        • Gelber RD
        Endocrine therapies of breast cancer.
        Semin Oncol. 1996; 23: 494-505
        • Lønning E
        • Lien EA
        Mechanisms of action of endocrine treatment in breast cancer.
        Crit Rev Oncol Hematol. 1995; 21: 158-193
        • Iveson TJ
        • Ahern J
        • Smith IE
        Response to third-line endocrine treatment for advanced breast cancer.
        Eur J Cancer. 1993; 29A: 572-574
        • Garcia-Giralt E
        • Ayme Y
        • Carton M
        • et al.
        Second and third line hormonotherapy in advanced post-menopausal breast cancer: A multicenter randomized trial comparing medroxyprogesterone acetate wi.
        Breast Cancer Res Treat. 1993; 24: 139-145
        • Murray R
        • Pitt P
        Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer.
        Breast Cancer Res Treat. 1995; 35: 249-253
        • Thürlimann B
        • Paridaens R
        • Serin D
        • et al.
        Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multi.
        Eur J Cancer. 1997; 33 (Exemestane Study Group): 1767-1773
        • Kiang DT
        • Frenning DH
        • Vosika GJ
        • Kennedy BJ
        Comparison of tamoxifen and hypophysectomy in breast cancer treatment.
        Cancer. 1980; 45: 1322-1325
        • Kurebayashi J
        • Sonoo H
        • Inaji H
        • et al.
        Endocrine therapies for patients with recurrent breast cancer: Predictive factors for responses to first- and second-line endocrine therapies.
        Oncology. 2000; 59: 31-37
        • Hortobagyi GN
        Endocrine treatment of breast cancer.
        in: Becker KL Principles and Practice of Endocrinology and Metabolism. 2nd ed. JB Lippincott, Philadelphia1995: 1868-1875
        • Vogel CL
        • Shemano I
        • Schoenfelder J
        • et al.
        Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer.
        J Clin Oncol. 1993; 11: 345-350
        • Stenbygaard LE
        • Herrstedt J
        • Thomsen JF
        • et al.
        Toremifene and tamoxifen in advanced breast cancer: A double-blind cross-over trial.
        Breast Cancer Res Treat. 1993; 25: 57-63
        • Sonoo H
        • Kurebayashi J
        • Iino Y
        • et al.
        Current status and controversial issues concerning endocrine therapy for patients with recurrent breast cancer in Japan.
        Breast Cancer. 1999; 6: 344-350
        • Eifel P
        • Axelson JA
        • Costa J
        • et al.
        National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1–3, 2000.
        J Natl Cancer Inst. 2001; 93: 979-989
        • National Comprehensive Cancer Network (NCCN)
        The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM].
        NCCN Breast Cancer Guideline, version 2.2002. February 1, 2002 (Accessed)
        • Aapro MS
        Adjuvant therapy of primary breast cancer: A review of key findings from the 7th International Conference.
        in: St. Gallen, February 2001Oncologist. 6. 2001: 376-385
        • Saez RA
        • Osborne CK
        Hormonal treatment of advanced breast cancer.
        in: Kennedy BJ Breast Cancer. Current Clinical Oncology. Vol. 1. Alan R. Liss, New York1989: 163-172
        • Gale KE
        • Andersen JW
        • Tormey DC
        • et al.
        Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group phase III trial comparing amino-glutethimide to tamoxifen.
        Cancer. 1994; 73: 354-361
        • Johannessen DC
        • Lønning PE
        Aromatase inhibitors in malignant diseases of aging.
        Drugs Aging. 1992; 2: 530-545
        • Buzdar AU
        • Jonat W
        • Howell A
        • et al.
        Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a c.
        Cancer. 1998; 83 (Arimidex Study Group): 1142-1152
        • Dombernowsky P
        • Smith I
        • Falkson G
        • et al.
        Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tol.
        J Clin Oncol. 1998; 16: 453-461
        • Kaufmann M
        • Bajetta E
        • Dirix LY
        • et al.
        Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomi.
        J Clin Oncol. 2000; 18 (Examestane Study Group): 1399-1411
        • Bonneterre J
        • Buzdar A
        • Nabholtz JM
        • et al.
        Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
        Cancer. 2001; 92: 2247-2258
        • Mouridsen H
        • Gershanovich M
        • Sun Y
        • et al.
        Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III stud.
        J Clin Oncol. 2001; 19: 2596-2606
        • Curran M
        • Wiseman L
        Drugs. 2001; 61 (Discussion 814): 807-813
        • Haller DG
        • Glick JH
        Progestational agents in advanced breast cancer: An overview.
        Semin Oncol. 1986; 13: 2-8
        • Wander HE
        • Kleeberg UR
        • Gartner E
        • et al.
        Megestrol acetate versus medroxyprogesterone acetate in the treatment of metastasizing breast cancers: Intermediate report of a multicenter phase III s.
        Onkologie. 1987; 10: 104-106
        • Muss HB
        • Case LD
        • Atkins JN
        • et al.
        Tamoxifen versus high-dose oral medroxy-progesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: A Piedmont Oncolo.
        J Clin Oncol. 1994; 12: 1630-1638
        • Stuart NS
        • Warwick J
        • Blackledge GR
        • et al.
        A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer.
        Eur J Cancer. 1996; 32A (Abstract): 1888-1892
        • Hultborn R
        • Johansson-Terje I
        • Bergh J
        • et al.
        Second-line endocrine treatment of advanced breast cancer: A randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide.
        Acta Oncol. 1996; 35: 75
        • Cheung KL
        • Roberston JF
        Expert Opin Investig Drugs. 2002; 11: 303-308
        • Jones SE
        • Webster A
        Greater duration of response with Faslodex® (fulvestrant) injection compared to Arimidex (anastrozole) in postmenopausal women with advanced breast c.
        Abstract presented at the American Association for Cancer Research 93rd Annual Meeting. April 6–10, 2002 (San Francisco, Calif.)
        • Vergote I
        for the Faslodex Trial 0020 and 0021 Investigators. Evidence of continued sensitivity to endocrine agents in postmenopausal women with advanced breast.
        Program and Abstracts of the 24th Annual San Antonio Breast Cancer Symposium. December 10–13, 2001 (San Antonio, Tex. Abstract 446)
        • Matelski H
        • Greene R
        • Huberman M
        • et al.
        Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer.
        Am J Clin Oncol. 1985; 8: 128-133
        • Stewart HJ
        • Forrest AP
        • Gunn JM
        • et al.
        The tamoxifen trial: A double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer.
        Eur J Cancer. 1980; : 83-88
        • Ribeiro GG
        A clinical trial to compare the use of tamoxifen vs. stilboestrol in the treatment of postmenopausal women with advanced breast cancer.
        Rev Endocr Relat Cancer. 1981; : 409-414
        • Westerberg H
        Tamoxifen and fluoxymesterone in advanced breast cancer: A controlled clinical trial.
        Cancer Treat Rep. 1980; 64: 117-121